

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner Novartis AG

Application No./Patent No.: 10/549,250

Filed/Issue Date: 18 May 2006

Titled 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Novartis AG

a Company

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)  
the patent application/patent identified above, by virtue of either

A ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy therefore is attached

OR

B ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at

Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at

Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at

Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO See MPEP 302.05]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
Signature

Ariene K. Musser

Printed or Typed Name

11 August 2010

Date

Attorney for Applicant

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

We  
Carlos GARCIA-ECHEVERRIA,  
Engelgasse 126, 4052 Basel, Switzerland  
Takanori KANAZAWA,  
27-8-203, Higashi-ara, Tsukuba-shi, Ibaraki Pref. 305-0033, Japan  
Eiji KAWAHARA,  
4-20, Inarima, Tsukuba-shi, Ibaraki Pref. 305-0061, Japan  
Keiichi MASUYA,  
1-2-1 Tsukuho, Tsukuba-shi, Ibaraki Pref. 300-3257, Japan  
Naoko MATSUURA,  
2-4-1-507, Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005, Japan  
Takshiro MIYAKE,  
2-4-1-102, Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005, Japan  
Osamu OHMORI,  
2-4-6-406, Sengen, Tsukuba-shi, Ibaraki Pref. 305-0047, Japan  
ichiro UNEMURA,  
2-3-7-406, Ninomiya, Tsukuba-shi, Ibaraki Pref. 305-0051, Japan

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to *Novartis AG, a Company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland*, its successors, assigns and legal representatives all my/our right, title and interest, in and for the United States of America, in and to the invention entitled:

**2, 4-DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS**

invented by me/us and described in the International application

No. PCT/EP2004/002616 filed 12 March 2004

and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by the said *Novartis AG*, its successors, assigns or other legal representatives, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to the said *Novartis AG*.

  
Carlos GARCIA ECHEVERRIA

Signed on


1709 2001

Takanori KANAZAWA

Signed on

Eiji KAWAHARA

Signed on

  
Keiichi MASUYA

Signed on

18.08.05

Naoko MATSUURA

Signed on

Takahiro MIYAKE

Signed on

Osamu OHNORI

Signed on

Ichiro UMEMURA

Signed on

Signed on

Carlos GARCIA-ECHVERRIA

Signed on

Takanori KANAZAWA

Signed on

Eiji KAWAHARA

Signed on

Koichi MASUYA

Signed on

Naoko MATSUURA

Signed on

Takahiro MIYAKE

Signed on

Osamu OHMORI

Signed on

Ichiro UMEMURA